tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2022-100-10-6-14tiblj-1679Research ArticleCOVID-19COVID-19Стратегия прокальцитонин-контролируемой антимикробной терапии в условиях пандемии COVID-19Strategy for Procalcitonin-Controlled Antimicrobial Therapy in the COVID-19 Pandemichttps://orcid.org/0000-0002-0934-7313ЗайцевА. А.ZaytsevA. A.

Зайцев Андрей Алексеевич, доктор медицинских наук, профессор, заслуженный врач РФ, главный пульмонолог

SPIN-код: 6549-5154

105229, Москва, Госпитальная площадь, д. 3

Тел.: +7 (499) 263-10-47

Andrey A. Zaytsev, Doctor of Medical Sciences, Professor, Honored Doctor of Russia, Chief Pulmonologist

SPIN-code: 6549-5154

3, Gospitalnaya Sq., Moscow, 105229

Phone: +7 (499) 263-10-47

a-zaicev@yandex.ruДроновИ. А.DronovI. A.

Дронов Иван Анатольевич, кандидат медицинских наук, доцент кафедры детских болезней, врач – клинический фармаколог Университетской детской клинической больницы

Москва

Ivan A. Dronov, Candidate of Medical Sciences, Associate Professor of Pediatric Diseases Department, Physician – Clinical Pharmacologist of the University Children's Clinical Hospital

Moscow

https://orcid.org/0000-0003-2009-3796КондратьеваТ. В.KondratievaT. V.

Кондратьева Татьяна Валерьевна, кандидат медицинских наук, врач-пульмонолог

Москва

Тел.: +7 (4967) 69-97-15

Tatiana V. Kondratieva, Candidate of Medical Sciences, Pulmonologist

Moscow

Phone: +7 (4967) 69-97-15

tanyakondratieva@mail.ruФГБУ «Главный военный клинический госпиталь им. Н. Н. Бурденко»; ФГБОУ ВО «Медицинский институт непрерывного образования МГУПП»РоссияBurdenko Main Military Clinical Hospital; Medical Institute of Continuing EducationRussian FederationФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова МЗ РФ (Сеченовский университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian FederationФГКУ «1586-й Военный клинический госпиталь» МО РФРоссияThe 1586th Military Clinical HospitalRussian Federation20220811202210010614Copyright © Зайцев А.А., Дронов И.А., Кондратьева Т.В., 20222022Зайцев А.А., Дронов И.А., Кондратьева Т.В.Zaytsev A.A., Dronov I.A., Kondratieva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1679

Цель обзора – оптимизировать применение антибактериальной терапии при COVID-19 на основании литературных и собственных данных. Принятие решения о назначении антибактериальной терапии при присоединении вторичной бактериальной пневмонии при SARS-CoV-2-ассоциированном поражении легких должно быть основано на комплексной оценке результатов клинического и лабораторно-инструментального обследования, в том числе повышения уровня прокальцитонина (более 0,5 нг/мл).

Для достижения этой цели использован анализ 48 источников литературы.

The objective of this review is to optimize the use of antibiotic therapy for COVID-19 based on the published and our own data. The decision to prescribe antibiotic therapy in case of secondary bacterial pneumonia associated with SARS-CoV-2 should be based on a comprehensive assessment of the results of clinical, laboratory and instrumental examination including the elevated level of procalcitonin (more than 0,5 ng/ml).

To achieve this objective, 48 publications were analyzed.

COVID-19биомаркеры воспаленияпрокальцитонинПКТ-контролируемая терапиявнебольничная пневмонияинтерстициопатия легкихCOVID-19biomarkers of inflammationprocalcitoninPCT-controlled therapycommunity-acquired pneumonialung interstitiopathyReferencesАвдеев С. А., Дехнич А. В., Зайцев А. А., Синопальников А. И., Козлов Р. С. и др. Внебольничная пневмония у взрослых. Клинические рекомендации РРО и МАКМАХ, 2021 // [Электронный ресурс]. URL: https://www.antibiotic.ru/files/306/kr654.pdf.Avdeev S.A., Dekhnich A.V., Zaytsev A.A., Sinopalnikov A.I., Kozlov R.S. et al. Vnebolnichnaya pnevmoniya u vzroslykh. Klinicheskiye rekomendatsii RRO i MAKMAKH, 2021. [Community-acquired pneumonia in adults. Clinical guidelines by RRS and IACMAC, 2021]. (Epub.), Available at: https://www.antibiotic.ru/files/306/kr654.pdf.Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 15 (22.02.2022 г.)» // [Электронный ресурс]. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/ВМР_COVID-19_V15.pdf.Vremennye metodicheskie rekomendatsii. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19) Versiya 15. 22.02.2022. [Provisional guidelines on prevention, diagnostics and treatment of the new coronavirus infection (COVID-19). Version 15. February 02, 2022]. (Epub.), Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/ВМР_COVID-19_V15.pdf.Зайцев А. А. Письмо в редакцию // Клиническая микробиология и антимикробная химиотерапия. ‒ 2020. – Т. 22, № 2. – C. 84-86. doi:10.36488/cmac.2020.2.84-86.Zaytsev A.A. Correspondence column. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2020, vol. 22, no. 2, pp. 84-86. (In Russ.) doi: 10.36488/cmac.2020.2.84-86.Зайцев А. А., Голухова Е. З., Мамалыга М. Л., Чернов С. А., Рыбка М. М., Крюков Е. В., Ключников И. В., Семенов В. Ю., Орлов И. Н. Эффективность пульс-терапии метилпреднизолоном у пациентов с COVID-19 // Клиническая микробиология и антимикробная химиотерапия. – 2020. – Т. 22, № 2. – P. 88-91. doi: 10.36488/cmac.2020.2.88-91.Zaytsev A.A., Golukhova E.Z., Mamaliga M.L., Chernov S.A., Rybka M.M., Kryukov E.V., Klyuchnikov I.V., Semenov V.Yu., Orlov I.N. Efficacy of methylprednisolone pulse therapy in patients with COVID-19. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya, 2020, vol. 22, no. 2, pp. 88-91. (In Russ.) doi: 10.36488/cmac.2020.2.88-91.Зайцев А. А., Овчинников Ю. В., Кондратьева Т. В. Анализ клинико-диагностических возможностей инструментов оценки тяжести и прогноза внебольничной пневмонии у пациентов молодого возраста из организованных коллективов // Пульмонология. – 2014. – № 5. – P. 67-72. https://doi.org/10.18093/0869-0189-2014-0-5-67-72.Zaytsev A.A., Ovchinnikov Yu.V., Kondratieva T.V. An analysis of diagnostic values of prognostic tools for community-acquired pneumonia in young patients in a closed community. Pulmonologiya, 2014, no. 5, pp. 67-72. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-5-67-72.Малеев В. В., Зайцев А. А., Яковлев С. В., Козлов Р. С. и др. О применении антибактериальной терапии у пациентов с новой коронавирусной инфекцией COVID-19 // Терпевтический архив. ‒ 2020. ‒ № 11. ‒ С. 4.Maleev V.V., Zaytsev A.A., Yakovlev S.V., Kozlov R.S. et al. On the use of antibiotic therapy in patients with the novel coronavirus infection of COVID-19. Terapevticheskiy Arkhiv, 2020, no. 11, pp. 4. (In Russ.)Моррисон В. В., Божедомов А. Ю. Значение определения концентрации прокальцитонина плазмы крови в диагностике септических состояний // Саратовский научный медицинский журнал. – 2010. – Т. 6, № 2. – P. 261-267.Morrison V.V., Bozhedomov A.Yu. The value of testing procalcitonin concentration in plasma in the diagnosis of septic conditions. Saratovsky Nauchny Meditsinskiy Journal, 2010, vol. 6, no. 2, pp. 261-267. (In Russ.)Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis // Lancet. – 2022. – № 399. – P. 629-655. doi: 10.1016/S0140-6736(21)02724-0.Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 2022, no. 399, pp. 629-655. doi: 10.1016/S0140-6736(21)02724-0.Assicot M., Gendrel D., Carsin H. et al. High serum procalcitonin concentrations in patients with sepsis and infection // Lancet. – 1993. – Vol. 341 (8844). – P. 515-518. doi: 10.1016/0140-6736(93)90277-n.Assicot M., Gendrel D., Carsin H. et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet, 1993, vol. 341 (8844), pp. 515-518. doi: 10.1016/0140-6736(93)90277-n.Bohuon C. A brief history of procalcitonin // Int. Care Med. – 2000. – Vol. 26 (S2). – P. 146-147. doi: 10.1007/BF02900727.Bohuon C. A brief history of procalcitonin. Int. Care Med., 2000, vol. 26 (S2), pp. 146-147. doi: 10.1007/BF02900727.Brechot N., Hekimian G. et al. Procalcitonin to guide antibiotic therapy in the ICU // Int. J. Antimicrob. Agents. – 2015. – Vol. 46 (Suppl. 1). – P. 19-24. doi: 10.1016/j.ijantimicag.2015.10.012.Brechot N., Hekimian G. et al. Procalcitonin to guide antibiotic therapy in the ICU. Int. J. Antimicrob. Agents, 2015, vol. 46, suppl. 1, pp. 19-24. doi: 10.1016/j.ijantimicag.2015.10.012.Calderon M., Li A., Bazo-Alvarez J., et al. Evaluation of procalcitonin-guided antimicrobial stewardship in patients admitted to hospital withCOVID-19 pneumonia // JAC Antimicrob. Resist. – 2021. – № 3. – dlab133. doi: 10.1093/jacamr/dlab133.Calderon M., Li A., Bazo-Alvarez J., et al. Evaluation of procalcitonin-guided antimicrobial stewardship in patients admitted to hospital with COVID-19 pneumonia. JAC Antimicrob. Resist., 2021, no. 3, dlab133. doi: 10.1093/jacamr/dlab133.Chen N., Zhou M. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. – 2020. – Vol. 395 (10223). – P. 507-513. doi: 10.1016/S0140-6736(20)30211-7.Chen N., Zhou M. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, vol. 395 (10223), pp. 507-513. doi: 10.1016/S0140-6736(20)30211-7.Chen T., Dai Z., Mo P. et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study // J. Gerontol. A Biol. Sci. Med. Sci. – 2020. – Vol. 75, № 9. – P. 1788-1795. doi: 10.1093/gerona/glaa089.Chen T., Dai Z., Mo P. et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J. Gerontol. A Biol. Sci. Med. Sci., 2020, vol. 75, no. 9, pp. 1788-1795. doi: 10.1093/gerona/glaa089.Chen X., Yang Y., Huang M. et al. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center // J. Med. Virol. – 2020. – Vol. 92, № 9. – P. 1572-1579. doi: 10.1002/jmv.25810.Chen X., Yang Y., Huang M. et al. Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center. J. Med. Virol., 2020, vol. 92, no. 9, pp. 1572-1579. doi: 10.1002/jmv.25810.Christ-Crain М., Opal S. Clinical review: The role of biomarkers in the diagnosis and management of community-acquired pneumonia // Crit. Care. – 2010. – Vol. 14, № 1. – P. 203. doi: 10.1186/cc8155.Christ-Crain М., Opal S. Clinical review: The role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit. Care, 2010, vol. 14, no. 1, pp. 203. doi: 10.1186/cc8155.Christ-Crain M., Stolz D. et al. Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia // Am. J. Respir. Crit. Care Med. – 2006. – № 174. – P. 84-93. doi: 10.1164/rccm.200512-1922OC.Christ-Crain M., Stolz D. et al. Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia. Am. J. Respir. Crit. Care Med., 2006, no. 174, pp. 84-93. doi: 10.1164/rccm.200512-1922OC.Cleland D., Eranki A. Procalcitonin. StatPearls; [Internet] // Treasure Island (FL): StatPearls Publishing. – 2020. http://www.ncbi.nlm.nih.gov/books/NBK539794/.Cleland D., Eranki A. Procalcitonin. StatPearls. Treasure Island (FL), StatPearls Publishing. 2020 (Epub.). http://www.ncbi.nlm.nih.gov/books/NBK539794/.España P., Capelastegui A. et al. Population Study of Pneumonia (PSoP) Group. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia // Eur. J. Clin. Microbiol. Infect. Dis. – 2012. – Vol. 31, № 12. – P. 3397-3405. doi: 10.1007/s10096-012-1708-5.España P., Capelastegui A. et al. Population Study of Pneumonia (PSoP) Group. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis., 2012, vol. 31, no. 12, pp. 3397-3405. doi: 10.1007/s10096-012-1708-5.Guan W., Liang W., Zhao Y. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis // Eur. Respir. J. – 2020. – Vol. 55, № 5. – P. 2000547. doi: 10.1183/13993003.00547-2020.Guan W., Liang W., Zhao Y. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J., 2020, vol. 55, no. 5, pp. 2000547. doi: 10.1183/13993003.00547-2020.Guan W., Ni Z., Hu Y. et al. China Medical Treatment Expert Group for COVID-19. Clinical characteristics of Coronavirus Disease 2019 in China // N. Engl. J. Med. – 2020. – Vol. 382, № 18. – P. 1708-1720. doi: 10.1056/NEJMoa2002032.Guan W., Ni Z., Hu Y. et al. China Medical Treatment Expert Group for COVID-19. Clinical characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med., 2020, vol. 382, no. 18, pp. 1708-1720. doi: 10.1056/NEJMoa2002032.Horie M., Ugajin M. et al. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia // Am. J. Med. Sci. – 2012. – Vol. 343, № 1. – P. 30-35. doi: 10.1097/MAJ.0b013e31821d33ef.Horie M., Ugajin M. et al. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia. Am. J. Med. Sci., 2012, vol. 343, no. 1, pp. 30-35. doi: 10.1097/MAJ.0b013e31821d33ef.Huang I., Pranata R., Lim M. et al. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis // Ther. Adv. Respir. Dis. – 2020. – № 14. – P. 1753466620937175. doi: 10.1177/1753466620937175.Huang I., Pranata R., Lim M. et al. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther. Adv. Respir. Dis., 2020, no. 14, pp. 1753466620937175. doi: 10.1177/1753466620937175.Ivan Hariyanto T., Kurniawan A. Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection // J. Med. Virol. – 2021. – Vol. 93, № 3. – P. 1832-1836. doi: 10.1002/jmv.26698.Ivan Hariyanto T., Kurniawan A. Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection. J. Med. Virol., 2021, vol. 93, no. 3, pp. 1832-1836. doi: 10.1002/jmv.26698.Julián-Jiménez A., Timón Zapata J. et al. Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department // Enferm. Infecc. Microbiol. Clin. – 2014. – Vol. 32, № 4. – P. 225-235. doi: 10.1016/j.eimc.2013.04.015.Julián-Jiménez A., Timón Zapata J. et al. Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department. Enferm. Infecc. Microbiol. Clin., 2014, vol. 32, no. 4, pp. 225-235. doi: 10.1016/j.eimc.2013.04.015.Karzai W., Oberhoffer M. et al. Procalcitonin - a new indicator of the systemic response to severe infections // Infection. – 1997. – Vol. 25, № 6. – P. 329-334. doi: 10.1007/BF01740811.Karzai W., Oberhoffer M. et al. Procalcitonin - a new indicator of the systemic response to severe infections. Infection, 1997, vol. 25, no. 6, pp. 329-334. doi: 10.1007/BF01740811.Kim J., Seo J. et al. Usefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumonia // Tuberc. Respir. Dis. – 2013. – Vol. 74, № 5. – P. 207-214. doi: 10.4046/trd.2013.74.5.207.Kim J., Seo J. et al. Usefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumonia. Tuberc. Respir. Dis., 2013, vol. 74, no. 5, pp. 207-214. doi: 10.4046/trd.2013.74.5.207.Kooistra E., van Berkel M., van Kempen N. et al. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients // Crit. Care. – 2021. – 25. – P. 281. doi: 10.1186/s13054-021-03717-z.Kooistra E., van Berkel M., van Kempen N. et al. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Crit. Care, 2021, 25, pp. 281. doi: 10.1186/s13054-021-03717-z.Krüger S., Ewig S. et al. CAPNETZ Study Group. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes // Eur. Respir. J. – 2008. – Vol. 31, № 2. – P. 349-355. doi: 10.1183/09031936.00054507.Krüger S., Ewig S. et al. CAPNETZ Study Group. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur. Respir. J., 2008, vol. 31, no. 2, pp. 349-355. doi: 10.1183/09031936.00054507.Kyriazopoulou E., Giamarellos-Bourboulis E. Antimicrobial stewardship using biomarkers: accumulating evidence for the critically // Antibiotics (Basel). – 2022. – Vol. 11, № 3. – P. 367. doi: 10.3390/antibiotics11030367.Kyriazopoulou E., Giamarellos-Bourboulis E. Antimicrobial stewardship using biomarkers: accumulating evidence for the critically. Antibiotics (Basel), 2022, vol. 11, no. 3, pp. 367. doi: 10.3390/antibiotics11030367.Lansbury L., Lim B., Baskaran V. et al. Co-infections in people with COVID-19: a systematic review and meta-analysis // J. Infect. – 2020. – Vol. 81, № 2. – P. 266-275. doi: 10.1016/j.jinf.2020.05.046.Lansbury L., Lim B., Baskaran V. et al. Co-infections in people with COVID-19: a systematic review and meta-analysis. J. Infect., 2020, vol. 81, no. 2, pp. 266-275. doi: 10.1016/j.jinf.2020.05.046.Moseley P., Jackson N., Omar A. et al. Single-centre experience of using procalcitonin to guide antibiotic therapy in COVID-19 intensive care patients // J. Hosp. Infect. – 2022. – № 119. – P. 194-195. doi: 10.1016/j.jhin.2021.10.010.Moseley P., Jackson N., Omar A. et al. Single-centre experience of using procalcitonin to guide antibiotic therapy in COVID-19 intensive care patients. J. Hosp. Infect., 2022, no. 119, pp. 194-195. doi: 10.1016/j.jhin.2021.10.010.Ponti G., Maccaferri M., Ruini C. et al. Biomarkers associated with COVID-19 disease progression // Crit. Rev. Clin. Lab. Sci. ‒ 2020. ‒ Р. 1-11. doi: 10.1080/10408363.2020.1770685.Ponti G., Maccaferri M., Ruini C. et al. Biomarkers associated with COVID-19 disease progression. Crit. Rev. Clin. Lab. Sci., 2020, pp. 1-11. doi: 10.1080/10408363.2020.1770685.Raess N., Schuetz P., Cesana-Nigro N. et al. Influence of prednisone on inflammatory biomarkers in community-acquired pneumonia: secondary analysis of a randomized trial // J. Clin. Pharmacol. – 2021. – Vol. 61, № 11. – P. 1406-1414. doi: 10.1002/jcph.1914.Raess N., Schuetz P., Cesana-Nigro N. et al. Influence of prednisone on inflammatory biomarkers in community-acquired pneumonia: secondary analysis of a randomized trial. J. Clin. Pharmacol., 2021, vol. 61, no. 11, pp. 1406-1414. doi: 10.1002/jcph.1914.Rohani P., Jude C., Chan K. et al. Chest Radiological Findings of Patients With Severe H1N1 Pneumonia Requiring Intensive Care // J. Int. Care Med. – 2016. ‒ Vol. 31, № 1. – P. 51-60. doi: 10.1177/0885066614538753.Rohani P., Jude C., Chan K. et al. Chest Radiological Findings of Patients With Severe H1N1 Pneumonia Requiring Intensive Care. J. Int. Care Med., 2016, vol. 31, no. 1, pp. 51-60. doi: 10.1177/0885066614538753.Schuetz P., Wirz Y., Sager R. et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections // Cochrane Database Syst Rev. – 2017. – Vol. 10, № 10. – CD007498. doi: 10.1002/14651858.CD007498.Schuetz P., Wirz Y., Sager R. et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev., 2017, vol. 10, no. 10, CD007498. doi: 10.1002/14651858.CD007498.Sun D., Li H., Lu X. et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study // World J. Pediatr. – 2020. – Vol. 16, № 3. – P. 251-259. doi: 10.1007/s12519-020-00354-4.Sun D., Li H., Lu X. et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J. Pediatr., 2020, vol. 16, no. 3, pp. 251-259. doi: 10.1007/s12519-020-00354-4.Tamura M., Watanabe M. et al. Serial quantification of procalcitonin (PCT) predicts clinical outcome and prognosis in patients with community-acquired pneumonia (CAP) // J. Infect. Chemother. – 2014. – № 2. – P. 97-103. doi: 10.1016/j.jiac.2013.09.005.Tamura M., Watanabe M. et al. Serial quantification of procalcitonin (PCT) predicts clinical outcome and prognosis in patients with community-acquired pneumonia (CAP). J. Infect. Chemother., 2014, no. 2, pp. 97-103. doi: 10.1016/j.jiac.2013.09.005.Ugajin M., Yamaki K. et al. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia // Respir. Care. – 2014. – Vol. 59, № 4. – P. 564-573. doi: 10.4187/respcare.02807.Ugajin M., Yamaki K. et al. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia. Respir. Care, 2014, vol. 59, no. 4, pp. 564-573. doi: 10.4187/respcare.02807.Upadhyay S., Niederman M. Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia? // Infect. Dis. Clin. North Am. – 2013. – Vol. 27, № 1. – P. 19-31. doi: 10.1016/j.idc.2012.11.003.Upadhyay S., Niederman M. Biomarkers: what is their benefit in the identification of infection, severity assessment, and management of community-acquired pneumonia? Infect. Dis. Clin. North Am., 2013, vol. 27, no. 1, pp. 19-31. doi: 10.1016/j.idc.2012.11.003.Vaughn V., Gandhi T., Petty L. et al. Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study // Clin. Infect. Dis. – 2020. – Vol. 72, № 10. – Р. e533-e541. doi: 10.1093/cid/ciaa1239.Vaughn V., Gandhi T., Petty L. et al. Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study. Clin. Infect. Dis., 2020, vol. 72, no. 10, pp. e533-e541. doi: 10.1093/cid/ciaa1239.Williams E., Mair L., de Silva T. et al. Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: A retrospective cohort study // J. Hosp. Infect. – 2021. – № 110. – P. 103-107. doi: 10.1016/j.jhin.2021.01.006.Williams E., Mair L., de Silva T. et al. Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: A retrospective cohort study. J. Hosp. Infect., 2021, no. 110, pp. 103-107. doi: 10.1016/j.jhin.2021.01.006.Wolfisberg S., Gregoriano C., Schuetz P. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19 // Crit. Rev. Clin. Lab. Sci. – 2022. – Vol. 59, № 1. – P. 54-65. doi: 10.1080/10408363.2021.1975637.Wolfisberg S., Gregoriano C., Schuetz P. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19. Crit. Rev. Clin. Lab. Sci., 2022, vol. 59, no. 1, pp. 54-65. doi: 10.1080/10408363.2021.1975637.Yunus I., Fasih A., Wang Y. The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics // PLoS One. – 2018. – Vol. 13, № 11. – Р. e0206527. doi: 10.1371/journal.pone.0206527.Yunus I., Fasih A., Wang Y. The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics. PLoS One, 2018, vol. 13, no. 11, pp. e0206527. doi: 10.1371/journal.pone.0206527.Zhang G., Hu C. et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China // J. Clin. Virol. – 2020. – № 127. – P. 104364. doi: 10.1016/j.jcv.2020.104364.Zhang G., Hu C. et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J. Clin. Virol., 2020, no. 127, pp. 104364. doi: 10.1016/j.jcv.2020.104364.Zhang J., Dong X., Cao Y. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China // Allergy. – 2020. – Vol. 75, № 7. – P. 1730-1741. doi: 10.1111/all.14238.Zhang J., Dong X., Cao Y. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 2020, vol. 75, no. 7, pp. 1730-1741. doi: 10.1111/all.14238.Zheng Zh., Peng F., Xu B. et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis // J. Infect. – 2020. – Vol. 81, № 2. – Р. e16-e25. doi: 10.1016/j.jinf.2020.04.021.Zheng Zh., Peng F., Xu B. et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J. Infect., 2020, vol. 81, no. 2, pp. e16-e25. doi: 10.1016/j.jinf.2020.04.021.Zhou F., Yu T. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study // Lancet. – 2020. – Vol. 395 (10229). – P. 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.Zhou F., Yu T. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, vol. 395 (10229), pp. 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

The authors declare that there are no conflicts of interest present.